Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.
Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.
The new R&D facility is a product of its new licensing deal with BridgeBio Pharma and will operate under Helsinn Therapeutics.
Shares of Enochian Biosciences plunged more than 36% after the Justice Department announced company cofounder Serhat Gumrukçu was arrested in a sordid 2018 murder-for-hire scheme.
A recent study published in Nature Medicine found that people who were vaccinated had a slightly decreased risk of getting Long COVID six months after their initial diagnosis.
Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.
Invectys is one of only a few companies investigating HLA-G, a natural immune checkpoint inhibitor, for solid tumors.
At the start of Takeda’s fiscal year on April 1, Ramona Sequeira and Julie Kim stepped into new positions on the company’s executive leadership team and became role models for women.
When the two new sites are up and running, Eli Lilly predicted the project will create up to 500 new jobs - with the expectation of four indirect jobs for each full-time position, based on industry data.
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations